Cite
HARVARD Citation
Godet, S. et al. (n.d.). Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO). American journal of hematology. 93 (2), pp. E52-E54. [Online].